Skip to main content

Table 3 Qualitative image analysis in the exploration and validation cohorts

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Group Excellent (score 5) Good (score 4) Average (score 3) Acceptable (score 2) Non-diagnostic (score 1) Average score
Exploration cohort
G1 (n = 46) 0 0 0 44 (95.7%) 2 (4.3%) 2.0 ± 0.2*
G2 (n = 46) 0 0 40 (87.0%) 6 (13.0%) 0 2.9 ± 0.3*
G3 (n = 46) 0 0 46 (100%) 0 0 3.0 ± 0.0*
G5 (n = 46) 0 43 (93.5%) 3 (6.5%) 0 0 3.9 ± 0.2*
G8 (n = 46) 10 (11.7%) 36 (78.3%) 0 0 0 4.2 ± 0.4*
Clinical validation cohort
G2 (n = 147) 0 0 143 (97.3%) 4 (2.7%) 0 3.0 ± 0.2*
G3 (n = 147) 0 1 (0.7%) 146 (99.3%) 0 0 3.0 ± 0.1*
G5 (n = 147) 0 85 (57.8%) 62 (42.2%) 0 0 3.6 ± 0.5*
G8 (n = 147) 8 (5.4%) 134 (91.2%) 5 (3.4%) 0 0 4.0 ± 0.3*
Gs (n = 147) 63 (42.9%) 84 (57.1%) 0 0 0 4.4 ± 0.5*
  1. Unless otherwise indicated, data are numbers of patients, and data in parentheses are percentages
  2. *Data are mean ± standard deviation (mean ± SD)
  3. Groups from the clinical validation cohort